Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Forte Biosciences, Inc. (FBRX) is the subject of a cash tender offer by Avena Merger Sub Inc., a wholly owned subsidiary of argenx. The offer seeks to acquire all outstanding Forte common shares at $77.00 per share in cash, net to the seller, without interest and subject to applicable withholding taxes.
argenx and Forte submitted Premerger Notification and Report Forms under the HSR Act on August 3, 2026, and the applicable waiting period expired at 11:59 p.m. Eastern Time on August 18, 2026. This expiration satisfies the HSR Clearance Condition, though the offer remains subject to the other conditions described in the Offer to Purchase.
Forte Biosciences, Inc. (FBRX) reports an update on the pending cash tender offer by Avena Merger Sub Inc., a wholly owned subsidiary of argenx BV, to purchase all outstanding Forte common shares at $77.00 per Share.
The amendment discloses that Forte and argenx filed Premerger Notification and Report Forms under the HSR Act on August 3, 2026, and that the required waiting period expired at 11:59 p.m. Eastern Time on August 18, 2026. The antitrust-related closing condition in the merger agreement tied to HSR waiting-period expiration has therefore been satisfied.
Forte Biosciences, Inc. has an updated ownership report from OrbiMed-related entities. OrbiMed Advisors LLC reports beneficial ownership of 1,264,980 shares of common stock, representing 6.2% of the class. OrbiMed Capital GP IX LLC reports 1,041,742 shares, or 5.1%, and OrbiMed Capital LLC reports 312,725 shares, or 1.5%.
OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC report shared voting and dispositive power over their positions, while OrbiMed Capital LLC reports sole voting and dispositive power over 312,725 shares. In the aggregate, the reporting persons hold 7.7% of Forte Biosciences’ common stock on behalf of other persons who have rights to dividends or sale proceeds. Investment and voting power is exercised through a management committee of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership.
Affinity Asset Advisors, LLC and its managing member Michael Cho report beneficial ownership in Forte Biosciences, Inc. common stock. Through Affinity Healthcare Fund, LP, they beneficially own 1,145,391 shares of common stock as of June 30, 2026, representing approximately 5.6% of Forte’s outstanding common stock.
The ownership is based on 20,478,817 shares of common stock outstanding as of May 6, 2026, as referenced in Forte’s public disclosures. Affinity Asset Advisors has sole voting and dispositive power over these shares pursuant to its investment management role, and Michael Cho may be deemed a beneficial owner through his position with the adviser.
Janus Henderson Group Ltd. reports beneficial ownership of 1,894,076 shares of Forte Biosciences, Inc. common stock, representing 9.3% of the class as of June 30, 2026. Janus Henderson’s affiliated asset managers hold shared voting and dispositive power over these shares, generally for client accounts referred to as Managed Portfolios.
The asset managers may be deemed beneficial owners through their investment and voting discretion, but the Managed Portfolios retain the right to receive all dividends and sale proceeds. Among these, Janus Henderson Biotech Innovation Master Fund Ltd. has rights to dividends or proceeds on more than 5% of Forte’s common stock, though it is not considered a separate reporting person due to an irrevocable delegation of investment and voting discretion to an asset manager.
Forte Biosciences, Inc. reported a larger net loss while advancing its lead autoimmune candidate FB102 and agreeing to be acquired. For the six months ended June 30, 2026, net loss was $45.5 million compared with $26.9 million a year earlier, driven mainly by higher FB102 clinical and manufacturing spend. Research and development expenses rose to $42.8 million, while general and administrative expenses declined to $4.2 million helped by $4.8 million of insurance recoveries related to prior litigation.
Cash, cash equivalents and short‑term investments totaled $198.5 million, supported by a $172.5 million April 2026 equity offering. Management believes this liquidity funds operations for at least 12 months. The company remains pre‑revenue with an accumulated deficit of $268.8 million.
FB102 generated positive Phase 1b data in celiac disease and non‑segmental vitiligo, and a Phase 1b alopecia areata study and a Phase 2 celiac trial are ongoing with topline data expected in the second half of 2026. On July 26, 2026, Forte agreed to be acquired by argenx BV via a cash tender offer at $77.00 per share followed by a merger, subject to customary conditions and a potential $65 million termination fee.
Adage Capital Management, L.P. and related parties report their ownership in Forte Biosciences, Inc. common stock. Adage Capital Partners, L.P. directly holds 700,000 shares of Forte Biosciences, Inc. (Common Stock, par value $0.001, CUSIP 34962G208).
This position represents 3.42% of the outstanding common stock, based on 20,478,817 shares outstanding as of May 6, 2026, as reported by the company for the quarter ended March 31, 2026. Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross share voting and dispositive power over these 700,000 shares, with no sole voting or dispositive power reported.
Glazer Capital, LLC and Paul J. Glazer report their ownership position in Forte Biosciences, Inc. common stock on a Schedule 13G. They report beneficial ownership of 300,000 shares of common stock, representing 1.46% of the outstanding class.
The reporting persons have no sole voting or dispositive power over these shares, but report shared voting and shared dispositive power over 300,000 shares held by certain funds and managed accounts for which Glazer Capital acts as investment manager. They state that, as of this report, they have ceased to be beneficial owners of more than five percent of the class of Forte Biosciences common stock.
Alger Associates, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Forte Biosciences, Inc. common stock. Alger reports beneficial ownership of 935,514 shares, representing 4.6% of the class. The firm holds 930,512 shares with sole voting power and 935,514 shares with sole dispositive power, with no shared voting or dispositive power. The securities are held through one or more open-end investment companies or other managed accounts advised by Fred Alger Management, LLC, an investment adviser wholly owned through intermediate holding companies by Alger Associates. Alger indicates it now holds 5 percent or less of the class.
Janus Henderson Group Ltd. reports beneficial ownership of Forte Biosciences, Inc. common stock. Through its investment adviser subsidiaries (the Asset Managers), it may be deemed to beneficially own 521,016 shares of common stock, including shares obtainable through warrant exercises, representing 2.5% of the class.
Janus Henderson has no sole voting or dispositive power over these shares but has shared voting and dispositive power over 521,016 shares. The shares are held in various client accounts referred to as Managed Portfolios, which have the right to receive all dividends and sale proceeds, and none of these portfolios individually owns more than five percent of Forte Biosciences’ common stock.